Sub-chronic lung inflammation after airway exposures to Bacillus thuringiensis biopesticides in mice by Barfod, Kenneth K et al.
RESEARCH ARTICLE Open Access
Sub-chronic lung inflammation after airway
exposures to Bacillus thuringiensis biopesticides in
mice
Kenneth K Barfod
1,2, Steen S Poulsen
3, Maria Hammer
1, Søren T Larsen
1*
Abstract
Background: The aim of the present study was to assess possible health effects of airway exposures to Bacillus
thuringiensis (Bt) based biopesticides in mice. Endpoints were lung inflammation evaluated by presence of
inflammatory cells in bronchoalveolar lavage fluid (BALF), clearance of bacteria from the lung lumen and
histological alterations of the lungs. Hazard identifications of the biopesticides were carried out using intratracheal
(i.t.) instillation, followed by an inhalation study. The two commercial biopesticides used were based on the Bt.
subspecies kurstaki and israelensis, respectively. Groups of BALB/c mice were i.t instilled with one bolus (3.5 × 10
5
or 3.4 × 10
6 colony forming units (CFU) per mouse) of either biopesticide. Control mice were instilled with sterile
water. BALFs were collected and the inflammatory cells were counted and differentiated. The BALFs were also
subjected to CFU counts.
Results: BALF cytology showed an acute inflammatory response dominated by neutrophils 24 hours after
instillation of biopesticide. Four days after instillation, the neutrophil number was normalised and inflammation was
dominated by lymphocytes and eosinophils, whereas 70 days after instillation, the inflammation was interstitially
located with few inflammatory cells present in the lung lumen.
Half of the instilled mice had remaining CFU recovered from BALF 70 days after exposure. To gain further knowl-
edge with relevance for risk assessment, mice were exposed to aerosols of biopesticide one hour per day for 2 × 5
days. Each mouse received 1.9 × 10
4 CFU Bt israelensis or 2.3 × 10
3 CFU Bt kurstaki per exposure. Seventy days after
end of the aerosol exposures, 3 out of 17 mice had interstitial lung inflammation. CFU could be recovered from 1
out of 10 mice 70 days after exposure to aerosolised Bt kurstaki. Plethysmography showed that inhalation of Bt
aerosol did not induce airway irritation.
Conclusions: Repeated low dose aerosol exposures to commercial Bt based biopesticides can induce sub-chronic
lung inflammation in mice, which may be the first step in the development of chronic lung diseases. Inhalation of
Bt aerosols does not induce airway irritation, which could explain why workers may be less inclined to use a filter
mask during the application process, and are thereby less protected from exposure to Bt spores.
Background
Regarded as harmless to humans, Bacillus thuringiensis
(Bt) is used worldwide as a commercial biopesticide for
the pest control of insects. It is typically used in large
spray campaigns on open fields or indoor in green
houses [1]. The insecticidal effect is largely due to the
characteristic ability to produce specific insect toxins
from crystal toxin genes mostly harboured on large plas-
mids [2]. Bt is a Gram positive, endospore-forming bac-
terium closely related to the opportunistic human
pathogen Bacillus cereus [3].
Commercial Bt strains have been isolated from human
faecal samples and nasal lavage cultures and elevated
human IgE antibody levels have been reported after
occupational exposure [4-6]. Most epidemiological and
occupational studies on biopesticides have focused on
immune responses, infection, food poisoning or other
gastro-intestinal symptoms [4,7-9]. The possible long-
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humans working with Bt biopesticides have not yet been
investigated, although the endospore sizes (1-2 μmi n
diameter) are within inhalable sizes for humans and
mice [10,11]. Long-term effect of biopesticide exposure
are not likely to be revealed in longitudinal epidemiolo-
gical studies, since many green house workers are only
temporary employed and therefore may have changed
occupation at the time of follow-up.
The purpose of the present study was to explore acute
and sub-chronic effects of airway exposure to biopesti-
cides, with focus on airway irritation, lung inflammation
and clearance of Bt from the lungs. Initially, dose-
response and time-response studies were conducted
using i.t. instillations. To simulate occupational expo-
sures, mice were in a subsequent experiment exposed
repeatedly by inhalation to aerosolised commercially for-
mulated biopesticides based on Bt israelensis or Bt
kurstaki.
Methods
Animals
The exposures were performed on BALB/cJ female mice
(Taconic M&B, Ry, Denmark), 6-8 weeks old, body
weight 18-22 g. Animals were housed up to 10 animals
per cage (425 × 266 × 150 mm) and drinking water and
food (Altromin no 1324 Brogaard Denmark) was pro-
vided ad libitum. Light/dark cycles were at 12 hours
and room temperature and relative humidity was kept at
19-22°C and 40-60%, respectively. All protocols were
approved by the Danish Animal Experiments
Inspectorate.
Bacterial suspensions and CFU determinations
The bacterial suspensions were prepared from commer-
cially available insecticides Vectobac® (Bt israelensis) and
Dipel® (Bt kurstaki) from Valent Biosciences (Sumitomo
Chemical Agro Europe, Lyon, France). The suspensions
for aerosol generation and intratracheal instillation were
prepared from the formulated products by suspending
them in sterile, endotoxin-free water. To reduce viscos-
ity (caused by additives) during the high dose instilla-
tions of Dipel®, mice in one group (experiment 4, cf.
Table 1) received product that was subjected to a wash-
ing procedure: the Dipel® was suspended and centri-
fuged and supernatant discharged. This procedure was
repeated twice. The final precipitate was re-suspended
in sterile water and adjusted for CFU counts.
All bacterial morphology and CFU determinations
w e r ep e r f o r m e do n c ef r o mt w op l a t e so fBacillus cereus
Selective Agar Base (BCSA) supplemented with Bacillus
cereus selective supplement and egg yolk emulsion
(Scharlau, Barcelona, Spain) after 24 hours of incubation
at 30°C.
Exposures
An overview of the experiments conducted is given in
Table 1. In order to reduce non-exposure related varia-
tion, the control group and exposure groups were run
simultaneously and all mice were handled by the same
staff.
Validation of inhaled dose and CFU recovery from BAL
fluids (experiments 1 and 2)
In order to validate the inhaled dose during the aerosol
exposure, two groups of 5 mice each were exposed to
two different concentrations of Vectobac® for one hour
and the lungs were excised at the end of exposure. The
theoretically inhaled dose per mouse was compared to
the actual deposited dose. The theoretically inhaled dose
was calculated as: aerosol concentration × the total
volume of inhaled air per mouse during the 60 min
exposure period. The aerosol concentration during the
exposure was calculated from the CFU determined by
Gesamtstaubprobenahme (GSP) filter sampler sampling
throughout the exposure (BGI Inc., Waltham, MA,
USA). The mean inhaled volume of air during one hour
exposure per mouse calculated from the obtained
respiration data (respiratory rate (min
-1) × tidal volume
(mL) × 60 min) and was determined to be 2.52 L/hour
per mouse. The actual deposited dose was determined
by CFU in the total lung homogenate (without a preced-
ing BAL procedure). CFU determinations performed
once on BCSA as described above.
In order to compare CFU recovery from total lung
homogenate to the CFU recovery from extracted BAL
fluid, 8 mice were exposed to Vectobac® via aerosol
exposure for 1 hour. BAL was performed on 4 mice and
the lungs were excised from all 8 mice and homoge-
nised. BAL fluids, homogenate of lavaged and unlavaged
lungs were all plated on BCSA plates for the determina-
tion of CFU as described and compared.
The aerosols were also monitored for particle size dis-
tribution during exposure by aerodynamic particle sizer
(APS-3321, TSI inc., Shoreview, MN, USA), and for
real-time particle counts by a Lighthouse 3016 particle
counter (LHPC) (Lighthouse Worldwide Solutions, Fre-
mont, CA, USA)
Intratracheal instillations (experiments 3-5)
T h em i c ew e r ea n e s t h e t i z e db e f o r ei n s t i l l a t i o nb yi n t r a
peritoneal injection with Hypnorm® (Veta Pharma Ltd.,
Leeds, UK) and Dormicum® (Roche AG, Basel, Switzer-
land). The mice were exposed intra tracheal (i.t.) once
with 50 μL volume of inoculum using a flexible poly-
ethylene tube attached to a syringe. The control animals
were instilled with 50 μL of sterile pyrogen-free water.
Correct insertion of the tube into the trachea was
assured by using a modified pneumotachometer
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ment, Copenhagen, Denmark) [12]. To establish a time-
response relationship (experiment 4), 10 mice per dose
were exposed by i.t instillations to either 3.4 × 10
6 CFU
Vectobac® or 3.5 × 10
5 CFU Dipel®.B A Lf l u i d sw e r e
collected 4 hours, 24 hours or 4 days post exposure and
cells were counted and differentiated as described below.
Subsequently, in order to establish a dose-response
relationship (experiment 3), 10 mice per dose was
exposed by i.t instillations to a Vectobac® dose of 1.25 ×
10
4,2×1 0
5,4 . 2×1 0
5 or 1.2 × 10
6 CFU, respectively.
BAL fluids were collected 24 hours post exposure and
cells were counted and differentiated as described below.
For the sub-chronic study (experiment 5) the instilled
doses were 3.4 × 10
6 CFU for Vectobac® and 3.5 × 10
5
for Dipel®.
Repeated aerosol inhalations (experiment 6)
Mice (n = 9 per group) were inserted into body plethys-
mographs that were connected to the exposure cham-
ber. The respiratory parameters were obtained for each
mouse from a Fleisch pneumotachograph connected to
each plethysmograph that allows continuously monitor-
ing of the parameters [13,14]. The exposures were pre-
ceded by a period that allowed the mice to adapt to the
plethysmographs. Then, a 15 min. period was used to
establish baseline (control) values of the respiratory
parameters. This period was followed by a 60 min.
exposure period and a 15 min recovery period. Mice
were exposed 60 min/day for 5 days per week for two
weeks with a two-day break in-between. The dose of 5
×1 0
4 CFU per mouse per exposure was chosen to
mimic occupational exposure [15]. Suspensions of bac-
teria were delivered from a glass syringe, administered
by an infusion pump (New England Medical Instru-
ments Inc., Medway, MA, USA) and via a polyethylene
tube connected to a Pitt. No. 1 aerosol generator [16].
The aerosol was mixed through a Vigreaux-column and
led to a glass/stainless steel exposure chamber as
described [17]. Total flow rate through the chamber was
20 L/min and the air input through the aerosol genera-
tor was 14 L/min. The aerosol generator and all related
equipments were thoroughly cleaned between exposure
sessions. During the aerosol exposures, air samples were
collected from the breathing zone of the mice for deter-
mination of particle size distribution, real-time particle
counts and aerosol CFU concentration. This was done
by APS at a flow of 5 L/min, LHPC at 2 L/min and by a
filter method GSP at 3.5 L/min. The APS monitored the
size distribution of particles in the range from 0.542 to
19.81 μm (aerodynamic diameter) in the exposure
chamber. Real time particle counts in the exposure
chamber was counted by LHPC in the ranges 0.7-2.0
μm and was used for a real time indicator of aerosol
concentration. The GSP samplers were mounted with
0.8 μm polycarbonate filters with airflow of 3.5 L/min.
All filters were extracted in 5 mL sterile 0.05% Tween-
80 in 0.9% NaCl solution by shaking for 15 min at room
temperature (500 rpm) in orbital shaking glass flasks
and serial dilutions were made for determination of
CFU (see above). Determination of respiratory para-
meters for assessment of irritation in upper respiratory
tract, conducting airways and alveolar region, respec-
tively was performed as thoroughly described [18].
Briefly, three types of effects from the respiratory system
can be studied simultaneously:
a) Sensory irritation. In humans, chemicals stimulating
the trigeminal nerve endings of the upper respiratory
Table 1 Experimental overview
Exp.
No.
Aim of experiment Number
of mice
Exposure
method
Substance Time
Endpoint
Endpoint Corresponding
figure
1 Validation of Inhalation dose 10 Inhalation
(1 hour)
Vectobac® 1 h CFU from total lung
homogenate
Figure 1
2 Validation of CFU recovery from BALF 8 Inhalation Vectobac® 1 h CFU from BALF and lavaged
lungtissue
None
3 Dose- response relationship B.t
israelensis
25 Instillation Vectobac® 24 h Inflammatory cells in BALF Figure 2
4 Time- response relationship B.t
israelensis or B.t kurstaki
42 Instillation Vectobac® or
Dipel®
(washed)
4h ,2 4h ,
4 days
CFU and inflammatory cells in
BALF
Figure 3
5 Sub-chronic effects of i.t instillations of
B.t israelensis or B.t kurstaki
20 Instillation Vectobac® or
Dipel®
70 days CFU, Inflammatory cells in
BALF, Histology
Figure 4
Figure 5
6 Sub-chronic effects of repeated
inhalations of B.t israelensis or B.t
kurstaki
18 Inhalation
(Repeated)
Vectobac® or
Dipel®
70 days Airway irritation, CFU,
Inflammatory cells in BALF,
Histology
Figure 5
Mice were exposed to Bt israelensis (Vectobac®) or Bt kurstaki (Dipel®) by either intratracheal instillation or inhalation of bacterial suspension. At 4 hours (h), 24 h,
4 days or 70 days after exposure, lungs were lavaged and the bronchoalveolar lavage fluid (BALF) was analysed for content of colony forming units (CFU) and
inflammatory cells. Furthermore, histological examination of the lung tissue was performed where specified.
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Page 3 of 10tract cause irritation that may increase to burning and
painful sensations, termed ‘sensory irritation’. Formalde-
hyde, ammonia and methacrolein are examples of com-
pounds being sensory irritants [18-20]. Sensory irritants
decrease the respiratory rate in mice due to a reflex
causing a break at the end of the inspiratory phase [21].
b) Bronchial constriction. Airflow limitation due to
bronchial constriction or inflammation of the conduct-
ing airways causes a lengthening of the duration of
expiration and thus causes an associated decrease in
respiratory rate. To quantify this effect, the airflow rate
during expiration is measured.
c) Pulmonary irritation is caused by stimulation of
vagal nerve endings at the alveolar level [22]. Stimula-
tion of this reflex is characterized by a pause at the end
of expiration, which is a specific marker of pulmonary
irritation. Ozone is an example of a substance inducing
pulmonary irritation [18].
The assessments and quantifications of the respiratory
frequency, time of inspiration, time of expiration, time
from end of inspiration until the beginning of expiration
termed “time of brake”,t i m ef r o me n do fe x p i r a t i o n
until beginning of the next inspiration termed “time of
pause”, tidal volume and mid-expiratory flow rate were
performed using the Notocord Hem software (Notocord
Systems SA, Croissy-sur-seine, France) as described in
details previously [23].
For the comparison of CFU recovered from total lung
homogenate to that of CFU recovered from BAL fluid, a
pilot inhalation experiment with 8 mice was performed.
BAL procedure
The BAL procedure was performed as previously
described with minor modifications (Larsen et al., 2007).
Briefly, the lungs were flushed four times with 0.8 mL
saline (0.9%) and the recovered fluids were pooled for
each mouse. From the BAL fluid of mice that have
received bacterial inocula, a 250 μLo ft o t a lf l u i dw a s
removed before centrifugation for CFU determination.
Cells were counted and differentiated by morphology
into neutrophils, lymphocytes, macrophages, epithelial
cells and eosinophils. For each sample, 200 cells were
differentiated.
Histopathology
The chest of the mice was opened and a polyethylene
tube introduced into the trachea. The polyethylene tube
was connected to a syringe containing 4% buffered par-
aformaldehyde, and the lungs were inflated in situ with
the fixative to normal size. After 5 minutes the lungs
were removed in toto and further fixated for at least 24
hours. Tissues were embedded in paraffin in a standar-
dized way (horizontal cut through the hilum regions)
and subsequently 7 μm thick slices were cut and stained
with haematoxylin/periodic acid Schiff (PAS). The
degree of inflammation and morphological changes in
the lungs were evaluated blindly by microscopy by two
experienced researchers and revaluated in case of discre-
pancy as described previously [24].
Statistics
The numbers of inflammatory cells in biopesticide-
exposed mice were compared to the control group by
means of non-parametric analysis of variance (Kruskall-
Wallis). In case of significant difference in the Kruskall-
Wallis test, pair-wise comparisons between the water
control group and the biopesticide-exposed animals
were further analysed using the Mann-Whitney’sU - t e s t .
Statistical significant difference was accepted at p < 0.05.
Results
Validation of actual deposited dose after inhalation
Comparing the theoretically inhaled dose of Vectobac®
(3.5 × 10
4 CFU) and actual deposited dose (2.9 × 10
4
CFU) revealed that 83% of the theoretically inhaled dose
was deposited. For the 10 × higher concentration, the
mean theoretically inhaled dose was 5.6 × 10
5 CFU and
actual deposited dose was 5.1 × 10
5 CFU, i.e. 91% was
deposited. The particle counts from APS and LHPC parti-
cle counters were stable throughout the exposure (Figure
1).
CFU recovery from BAL fluid and from total lung
homogenate
Comparison of the CFU present in total lung homoge-
nate to the CFU recovered from BAL fluid revealed that
an average of 13% (range 10-20%) of the total CFU was
recovered by the BAL procedure. The remaining 80-90%
of the CFUs were recovered from the lung homogenate
of the flushed lungs.
Acute inflammatory response to biopesticide instillation
A clear dose-dependent increase in number of neutro-
phils was apparent 24 hours post i.t. instillation of the
biopesticide Vectobac®. Statistically significant increased
numbers of neutrophils were seen after instillation of 2
×1 0
5 CFU or more. Furthermore, at the 1.2 × 10
6 CFU
Vectobac®dose a significant increased number of lym-
phocytes and eosinophils were seen (Figure 2).
The inflammatory responses seen as neutrophils in
BALF due to Vectobac® and Dipel® exposures were simi-
l a ro v e rt i m ea sa p p a r e n tf r o m( F i g u r e3 ) .N oc h a n g ei n
cell count or distribution was observed 4 hours after
instillation compared to that of the vehicle (sterile water)
control groups, but 24 hours post exposure, a signifi-
cantly increased number of neutrophils were observed
for Dipel® (p = 0.03) as well as Vectobac® (p = 0.0001).
Four days after exposure, elevated numbers of
Barfod et al. BMC Microbiology 2010, 10:233
http://www.biomedcentral.com/1471-2180/10/233
Page 4 of 10macrophages and neutrophils were seen for both Dipel®
and Vectobac®. Furthermore, exposure to Vectobac® gave
rise to an increased number of eosinophils (Figure 3).
Assessment of acute airway irritation after exposure to
biopesticide aerosols
For both Vectobac® and Dipel®, nine mice were exposed
to aerosolised product in the head-only exposure cham-
ber. The aerosols were monitored for both particle
counts by LHPC and for size-distribution by APS. The
majority of the particles in the generated aerosol were
between 0.8 and 2.0 μm with a peak count at 1 μm,
which is equal to the size of Bt spores [25]. Each mouse
received a theoretically inhaled dose of 1.9 × 10
4 CFU
Bt israelensis or 2.3 × 10
3 CFU Bt kurstaki per exposure.
Respiratory parameters were collected during the first 60
min of exposure to assess airway irritation. The results
showed no alterations in respiratory rate, time of brake
or time of pause when compared to baseline levels, i.e.
airway irritation was apparent neither from the nose nor
from the lungs (data not shown).
Recovery of CFU from the sub-chronic (70 days)
inhalation and aerosol studies
All BAL fluids from the sub-chronic studies were also
subjected to a CFU count (Figure 4). In the mice
instilled with 3.4 × 10
6 CFU Vectobac® (8 of 10 mice)
bacteria were still present in the BALF with an average
of 150 CFU/BALF. Only one mouse out of 9 instilled
with 3.5 × 10
5 CFU Dipel® had CFU recovered after 70
days (2850 CFU/BALF). In the mice exposed by inhala-
tion to Dipel® aerosols, one mouse out of 10 had CFU
recovered (630 CFU/BALF). No CFU was recovered
from mice exposed to Vectobac® aerosol.
Histopathology from the sub-chronic (70 days) studies
(experiments 5 and 6)
Effects of i.t. instillation
All 20 mice that received high doses of biopesticide by
i.t. instillation showed tissue changes for both commer-
cial products 70 days after exposure. The most pro-
nounced changes were observed in the group given
Vectobac®. The changes were localized in focal areas
Figure 1 Aerosol characteristics and validation of actual deposited dose (ADD) per mouse. Particles (counts min
-1) of the Vectobac® × 10
exposure aerosol were measured by APS (n= 21) and LHPC (n = 24) for different particle sizes. The theoretically inhaled dose (TID) per mouse
based on CFU measurements from a GSP filter sampler were compared to the ADD per mouse (n = 5 per group) for the two different exposure
concentrations. Values are means with SEM.
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Page 5 of 10Figure 2 Cells in BAL fluid after instillation of different doses of biopesticide. Mean number of cells in bronchoalveolar lavage (BAL) fluid
from mice (n = 5 per group) 24 hours after intratracheal instillation of Vectobac® biopesticide. Sterile water served as vehicle and was used for
dilutions. For each mouse, 200 cells were counted and differentiated. Values are means with SEM.
Figure 3 Cells in BAL fluid at different time points after instillation of biopesticide. Mean number of cells in bronchoalveolar lavage (BAL)
fluid from mice (n = 10 per group) 4 hours, 24 hours or 4 days after intratracheal instillation of Vectobac® or Dipel® biopesticide. Instilled doses
of biopesticide were 3.4 × 10
6 CFU/mouse for Vectobac® and 3.5 × 10
5 CFU/mouse for Dipel®. Sterile water served as vehicle and was used for
dilutions. For each mouse, 200 cells were counted and differentiated. Values are means with SEM.
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Page 6 of 10adjacent to the larger blood vessels. The dominating cell
type was lymphocytes but also plenty of neutrophils and
macrophages containing particles were present. The
PAS positive material is unidentified material from the
biopesticide remaining in the lungs. The sub-chronic
inflammation was apparent as small patches of intersti-
tial inflammation, affecting approximately 5% of the
lung surface. The degree of inflammation varied consid-
erably within the lung with the most pronounced
changes being localized to the lower, posterior part of
the lung and only minor changes were observed in the
peripheral parts of the lung tissue. Slight interstitial
inflammation was observed after Vectobac® instillation
(Figures 5C-E). In the larger bronchi, goblet cell forma-
tions comparable to experimental bronchitis was
observed.
Instillation of Dipel® resulted in fewer and less intense
changes. The typical changes were small focal areas with
accumulation of inflammatory cells interstitially and
inflammation was observed also peripherally even to the
level of the pleura (Figure 5F).
Effects of aerosol exposure
Histology suggested that one mouse had developed leu-
kaemia. In consequence, data from this mouse was
excluded from further analyses. In 3 of the remaining 17
mice, some patches of interstitial inflammation were
observed 70 days after end of the repeated exposures to
Vectobac® (Figure 5G and 5H), whereas exposure to
Dipel® gave rise to less significant effects (not shown).
Discussion
The Bt based biopesticides are generally considered a
safe and greener alternative to chemical pesticides. The
commercial Bt species are believed to be non-infectious
and have only on rare occasions been associated with
opportunistic infections in humans. Nevertheless, the
close relationship between Bt and the human pathogen
Bacillus cereus continues to be substantiated and gives
rise to new questions [26-29].
T h ep r e s e n ts t u d ys h o w e dt h a ti n s t i l l e do re v e n
inhaled Bt spores may be present in the lung and
extracted by BAL 70 days after administration. Our data
are in line with other clearance studies, demonstrating
CFU of Bt kurstaki in the liver, spleen and lungs 21
days after intratracheal (i.t.) instillation and similar pat-
terns were seen with Bt aizawai and B. subtilis. Clear-
ance patterns after i.v. injection with 10
7 CFU per
animal is also reported for Bt kurstaki, Bt israelensis, B.
subtilis and B. sphaericus. All strains were still recovered
from inner organs at the termination of the study (day
57 for Bt israelensis and 128 for Bt kurstaki) [30,31].
As Bt formulations are used for spray application,
hazard identification and risk assessment should be
based on airway effects. To our knowledge, the present
study is the first to investigate airway irritation and
Figure 4 Number of residual CFU recovered from BAL fluid 70 days after instillation. For Vectobac® the value is mean with SEM for the
responding mice (8 out of 10). For Dipel® instillation or Dipel® inhalation, data represent residual CFU from 1 out of 9 and 1 out of 10 mice,
respectively.
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Page 7 of 10Figure 5 Lung histology sections from mice 70 days after exposure to biopesticide. Arrows indicate interstitial inflammation with PAS
positive foreign materials. Exposures were 50 μL of sterile pyrogen-free water (Controls), Vectobac® or Dipel® through a single intratracheal
instillation (A-F) or repeated (2 × 5 × 1 h) aerosol exposures (G-H). Control slides (A-B) show the pulmonalis and bronchiole wall and with no
inflammatory changes. Interstitial inflammation is apparent after Vectobac® instillation (C-E) as indicated by arrows. Instillation of Dipel® resulted
in small focal areas with accumulation of inflammatory cells interstitially and inflammation was observed also peripherally even to the level of
the pleura (F). Patches of interstitial inflammation were also observed in 3 out of 17 mice after repeated aerosol exposures to Vectobac® (G-H).
Sections are stained with periodic acid-Schiff (PAS). Magnifications were ×32 (F), ×80 (A, C, D, E), ×200 (B, G) or ×320 (H).
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Page 8 of 10airway inflammation induced by inhalation of commer-
cial Bt biopesticides. The i.t. instillation of biopesticide,
showed that a single exposure gave rise to focal areas of
lung tissue inflammation still detectable 70 days after
exposure. A clear dose-response relationship was seen.
Inflammation was also seen 70 days after repeated inha-
lation of Bt biopesticide, although the effects after inha-
lation were less vigorous than after instillation. The
sub-chronic inflammation was apparent as small patches
of interstitial inflammation, a response that was not
detectable in the corresponding BAL fluid. The sub-
chronic inflammation observed in the present study, was
most likely due to the prolonged presence of Bt spores
or other product residues in the lungs, triggering and
maintaining the inflammatory response. This should be
seen in the light that the formulated biopesticides con-
tains only about 2% spores and 98% other ingredients
according to manufacturer which makes long term inha-
lation studies using the final formulated biopesticide
important. The list of other ingredients besides water is
known to authorities (e.g. the EPA) and approved for
other purposes e.g. a “food- carbohydrate” and preserva-
tives [32]. Most of these other ingredients have probably
not been subjected to long term inhalation studies in
animals as this was not their intended use. Therefore
alternative inoculums or controls, including spore free
or heat-inactivated biopesticide or specific excipients/
additives should also be studied for biological effect. In
the case of low clearance rates, as demonstrated in this
study, the inflammation could be prolonged or even
become chronic which may potentially initiate the devel-
opment of severe health effects such as chronic obstruc-
tive pulmonary disease [33] or formation of fibrotic lung
tissue [34].
In experiments 3, 5 and 6 the exposure concentrations
of Dipel® were almost a 10-fold lower than Vectobac®
and the lower effects and tissue changes of the expo-
sures with Dipel® should be seen in this light. This dif-
f e r e n c ei sa l s os h o w na st h er e c o v e r yo fC F Us t i l l
present in the BAL fluids 70 days after instillation with
different inoculums of two biopesticides. The lower con-
centrations were chosen on the basis of experiment 4,
where a washing procedure of the Dipel® product was
necessary due to viscosity. A pilot experiment revealed
that the washing procedure did not change the inflam-
matory properties of the product. Upon dilution of the
Dipel®, the viscosity was acceptable for instillation,
wherefore suspensions of the unaltered commercial
Dipel® product were used.
Our study has also demonstrated that exposure to
aerosolized Vectobac® did not induce airway irritation
upon inhalation. This is important in regards to occupa-
tional hazard as the absence of discomfort by exposure
would make workers less inclined to wear the
recommended protective filter facemask while working
with the biopesticide.
Conclusions
Repeated exposure to biopesticide aerosols may lead to
sub-chronic lung inflammation which may contribute to
the development of severe lung diseases. No airway irri-
tation was observed upon inhalation of Bt aerosols, sug-
gesting that exposure will not evoke a warning signal,
making the exposure insidious.
The present study emphasises the need for additional
studies assessing lung effects after long-term, repeated
exposures to low and occupationally relevant concentra-
tions of Bt biopesticide aerosols.
List of abbreviations used
APS: Aerodynamic particle sizer; ADD: Actual deposited
dose; BAL(F): Bronchoalveolar lavage (fluids); BCSA:
Bacillus cereus selective agar; Bt: Bacillus thuringiensis;
CFU: Colony forming units; COPD: Chronic obstructive
pulmonary disease; GSP: Gesamtstaubprobenahme sam-
pler; I.t.: Intra tracheal; LHPC: Lighthouse handheld par-
ticle counter; NOEL: No-observed effect level; PAS:
Periodic acid Schiff; TID: Theoretically inhaled dose
Acknowledgements
This work was in part supported by ilochip A/S, Denmark. We thank Gitte B.
Kristensen, Michael Guldbrandsen and Heidi Paulsen for excellent technical
support.
Author details
1National Research Centre for the Working Environment, Copenhagen,
Denmark.
2Statens Serum Institut, Copenhagen Denmark.
3Department of
Biomedical Research, The Panum Institute, University of Copenhagen,
Copenhagen, Denmark.
Authors’ contributions
KKB, MHA and STL designed the studies and planned the experiments. KKB,
MHA and SSP conducted the laboratory work. KKB, SSP and STL interpreted
the data. KKB drafted the first version of the manuscript. All authors
contributed to and approved the final manuscript.
Received: 25 May 2010 Accepted: 3 September 2010
Published: 3 September 2010
References
1. Glare RTravis, O’Callaghan Maureen: Bacillus thuringiensis: Biology, Ecology
and Safety John Wiley and Sons, LTD 2000.
2. Schnepf E: Bacillus thuringiensis and its pesticidal crystal proteins.
Microbiol Mol Biol Rev 1998, 62:775-806.
3. Drobniewski FA: Bacillus cereus and related species. Clin Microbiol Rev
1993, 6:324-338.
4. Doekes G, Larsen P, Sigsgaard T, Baelum J: IgE sensitization to bacterial
and fungal biopesticides in a cohort of Danish greenhouse workers: the
BIOGART study. Am J Ind Med 2004, 46:404-407.
5. Elliott JL, Sokolow R, Heumann M, Elefant SL: An exposure characterization
of a large scale application of a biological insecticide, Bacillus
thuringiensis. Applied Industriel Hygiene 1988, 3:119-122.
6. Jensen GB, Larsen P, Jacobsen BL, Madsen B, Wilcks A, Smidt L, et al:
Isolation and characterization of Bacillus cereus-like bacteria from faecal
samples from greenhouse workers who are using Bacillus thuringiensis-
based insecticides. Int Arch Occup Environ Health 2002, 75:191-196.
Barfod et al. BMC Microbiology 2010, 10:233
http://www.biomedcentral.com/1471-2180/10/233
Page 9 of 107. Bernstein IL, Bernstein JA, Miller M, Tierzieva S, Bernstein DI, Lummus Z,
et al: Immune responses in farm workers after exposure to Bacillus
thuringiensis pesticides. Environ Health Perspect 1999, 107:575-582.
8. Illing HP: Is working in greenhouses healthy? Evidence concerning the
toxic risks that might affect greenhouse workers. Occup Med (Lond) 1997,
47:281-293.
9. Noble MA, Riben PD, Cook GJ: Microbial and Epidemiological Surveillance
Programme to Monitor the Health Effects of Foray 48B BTK Spray. Report
to the Ministry of Forests, Province of British Columbia, Vancouver, Canada
1992, Ref Type: Report.
10. Carrera M, Zandomeni RO, Fitzgibbon J, Sagripanti JL: Difference between
the spore sizes of Bacillus anthracis and other Bacillus species. J Appl
Microbiol 2007, 102:303-312.
11. Menache MG, Miller FJ, Raabe OG: Particle inhalability curves for humans
and small laboratory animals. Ann Occup Hyg 1995, 39:317-328.
12. Jacobsen NR, Moller P, Jensen KA, Vogel U, Ladefoged O, Loft S, et al: Lung
inflammation and genotoxicity following pulmonary exposure to
nanoparticles in ApoE-/- mice. Part Fibre Toxicol 2009, 6:2.
13. Vijayaraghavan R, Schaper M, Thompson R, Stock MF, Boylstein LA, Luo JE,
et al: Computer assisted recognition and quantitation of the effects of
airborne chemicals acting at different areas of the respiratory tract in
mice. Arch Toxicol 1994, 68:490-499.
14. Boylstein LA, Luo J, Stock MF, Alarie Y: An attempt to define a just
detectable effect for airborne chemicals on the respiratory tract in mice.
Arch Toxicol 1996, 70:567-578.
15. Jensen GB, Larsen P, Jacobsen BL, Madsen B, Smidt L, Andrup L: Bacillus
thuringiensis in fecal samples from greenhouse workers after exposure
to B. thuringiensis-based pesticides. Appl Environ Microbiol 2002,
68:4900-4905.
16. Wong KL, Alarie Y: A method for repeated evaluation of pulmonary
performance in unanesthetized, unrestrained guinea pigs and its
application to detect effects of sulfuric acid mist inhalation. Toxicol Appl
Pharmacol 1982, 63:72-90.
17. Clausen SK, Bergqvist M, Poulsen LK, Poulsen OM, Nielsen GD:
Development of sensitisation or tolerance following repeated OVA
inhalation in BALB/cJ mice. Dose-dependency and modulation by the Al
(OH)(3) adjuvant. Toxicology 2003, 184:51-68.
18. Nielsen GD, Hougaard KS, Larsen ST, Hammer M, Wolkoff P, Clausen PA,
et al: Acute airway effects of formaldehyde and ozone in BALB/c mice.
Hum Exp Toxicol 1999, 18:400-409.
19. Nielsen GD, Wolkoff P, Alarie Y: Sensory irritation: Risk assessment
approaches. Regul Toxicol Pharmacol 2007, 48:6-18.
20. Larsen ST, Nielsen GD: Effects of methacrolein on the respiratory tract in
mice. Toxicol Lett 2000, 114:197-202.
21. Alarie Y: Computer-based bioassay for evaluation of sensory irritation of
airborne chemicals and its limit of detection. Arch Toxicol 1998,
72:277-282.
22. Vijayaraghavan R, Schaper M, Thompson R, Stock MF, Alarie Y:
Characteristic modifications of the breathing pattern of mice to evaluate
the effects of airborne chemicals on the respiratory tract. Arch Toxicol
1993, 67:478-490.
23. Larsen ST, Hansen JS, Hammer M, Alarie Y, Nielsen GD: Effects of mono-2-
ethylhexyl phthalate on the respiratory tract in BALB/c mice. Hum Exp
Toxicol 2004, 23:537-545.
24. Roursgaard M, Poulsen SS, Kepley CL, Hammer M, Nielsen GD, Larsen ST:
Polyhydroxylated C60 fullerene (fullerenol) attenuates neutrophilic lung
inflammation in mice. Basic Clin Pharmacol Toxicol 2008, 103:386-388.
25. Carrera M, Zandomeni RO, Fitzgibbon J, Sagripanti JL: Difference between
the spore sizes of Bacillus anthracis and other Bacillus species. J Appl
Microbiol 2007, 102:303-312.
26. Carlson CR, Kolsto AB: A complete physical map of a Bacillus
thuringiensis chromosome. J Bacteriol 1993, 175:1053-1060.
27. Helgason E: Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis
one species on the basis of genetic evidence. Appl Environ Microbiol 2000,
66:2627-2630.
28. Salamitou S: The plcR regulon is involved in the opportunistic properties
of Bacillus thuringiensis and Bacillus cereus in mice and insects.
Microbiology 2000, 146:2825-2832.
29. Wilcks A, Smidt L, Bahl MI, Hansen BM, Andrup L, Hendriksen NB, et al:
Germination and conjugation of Bacillus thuringiensis subsp. israelensis
in the intestine of gnotobiotic rats. J Appl Microbiol 2008, 104:1252-1259.
30. McClintock JT, Sjoblad RD: A comparative review of the mammalian
toxicity of bacillus thuringiensisbased pesticides. Pesticide Science 1995,
45:95-105.
31. Siegel JP, Shadduck JA: Clearance of Bacillus sphaericus and Bacillus
thuringiensis ssp. israelensis from mammals. J Econ Entomol 1990,
83:347-355.
32. Valent Biosciences: Dipel® Foray®. Forest Technical Manual 2001, 28-29.
33. Barnes PJ: Immunology of asthma and chronic obstructive pulmonary
disease. Nat Rev Immunol 2008, 183-192.
34. Pardo A, Barrios R, Gaxiola M, Segura-Valdez L, Carrillo G, Estrada A, et al:
Increase of lung neutrophils in hypersensitivity pneumonitis is
associated with lung fibrosis. Am J Respir Crit Care Med 2000,
161:1698-1704.
doi:10.1186/1471-2180-10-233
Cite this article as: Barfod et al.: Sub-chronic lung inflammation after
airway exposures to Bacillus thuringiensis biopesticides in mice. BMC
Microbiology 2010 10:233.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Barfod et al. BMC Microbiology 2010, 10:233
http://www.biomedcentral.com/1471-2180/10/233
Page 10 of 10